Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:12:14 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:BBIO - BRIDGEBIO PHARMA INC - https://bridgebio.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BBIO - Q0.346.11·47.241.046.51-0.23-0.52,139.298,63120,58947.05  47.36  46.13548.6809  21.7219:39:50Jun 3015 min RT 2¢

Recent Trades - Last 10 of 20589
Time ETExPriceChangeVolume
19:39:50Q46.11-0.631
19:23:47Q47.200.462
18:41:56Q47.240.5025
18:16:37Q47.250.5120
17:41:36Q47.240.501
17:40:40Q46.11-0.633
17:01:01Q46.11-0.633
16:32:55Q46.51-0.2333,482
16:29:00Q47.240.501
16:20:00Q46.51-0.23199

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-30 07:30U:BBIONews ReleaseBridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA(TM) European Royalty
2025-06-26 07:30U:BBIONews ReleaseBridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
2025-06-02 07:30U:BBIONews ReleaseBridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
2025-05-20 07:30U:BBIONews ReleaseAcoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
2025-05-19 12:34U:BBIONews ReleaseEarly and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
2025-05-14 16:01U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-05-13 07:30U:BBIONews ReleaseFirst Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
2025-05-12 07:30U:BBIONews ReleaseBridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
2025-05-07 07:30U:BBIONews ReleaseBridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
2025-04-29 16:01U:BBIONews ReleaseBridgeBio Reports First Quarter 2025 Financial Results and Business Updates
2025-04-28 05:00U:BBIONews ReleaseBEYONTTRA(TM) (acoramidis), the First Near-complete TTR Stabilizer (>=90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
2025-04-22 07:31U:BBIONews ReleaseBridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
2025-04-11 16:01U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-03-31 10:00U:BBIONews ReleaseAcoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
2025-03-27 07:00U:BBIONews ReleaseBeyonttra(TM) (acoramidis), the First Near-complete TTR Stabilizer (>=90%), Approved in Japan to Treat ATTR-CM
2025-03-24 07:30U:BBIONews ReleaseBridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
2025-03-21 16:00U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-03-17 16:01U:BBIONews ReleaseBridgeBio Announces CFO Succession
2025-02-26 02:50U:BBIONews ReleaseBridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
2025-02-24 16:10U:BBIONews ReleaseBridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt